<H1>Chapter DOI: 10.1007/978-1-60327-829-4_6<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>94</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>92</td></tr><tr><td>BibStructured Count</td><td width="10%">94</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>78</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>1</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>3</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>3</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_6</td><td>BibArticle</td><td>Isurugi K, Fukutani K, Ishida H, Hosoi Y. Endocrine effects of cyproterone acetate in patients with prostatic cancer. J Urol 1980; 123(2):180&#8211;183.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_6</td><td>BibArticle</td><td>Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 1992; 267(2):968&#8211;974.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_6</td><td>BibArticle</td><td>Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 2006; 23(8):1641&#8211;1658.</td><td><a href=http://dx.doi.org/10.1007/s11095-006-9024-3>10.1007/s11095-006-9024-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_6</td><td>BibArticle</td><td>Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N et al. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 2003; 63(1):211&#8211;223.</td><td><a href=http://dx.doi.org/10.1124/mol.63.1.211>10.1124/mol.63.1.211</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_6</td><td>BibArticle</td><td>Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 1988; 34(6):633&#8211;636.</td><td><a href=http://dx.doi.org/10.1007/BF00615229>10.1007/BF00615229</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_6</td><td>BibArticle</td><td>Creaven PJ, Pendyala L, Tremblay D. Pharmacokinetics and metabolism of nilutamide. Urology 1991; 37(Suppl 2):13&#8211;19.</td><td><a href=http://dx.doi.org/10.1016/0090-4295(91)80096-P>10.1016/0090-4295(91)80096-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_6</td><td>BibArticle</td><td>Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149(1):77&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_6</td><td>BibArticle</td><td>Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD, Dalton JT. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996; 26(2):117&#8211;122.</td><td><a href=http://dx.doi.org/10.3109/00498259609046693>10.3109/00498259609046693</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_6</td><td>BibArticle</td><td>Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 1996; 47(Suppl 1A):13&#8211;25.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(96)80003-3>10.1016/S0090-4295(96)80003-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_6</td><td>BibArticle</td><td>Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277(29):26321&#8211;26326.</td><td><a href=http://dx.doi.org/10.1074/jbc.M203310200>10.1074/jbc.M203310200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_6</td><td>BibArticle</td><td>Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20(13):3001&#8211;3015.</td><td><a href=http://dx.doi.org/10.1200/JCO.2002.10.018>10.1200/JCO.2002.10.018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_6</td><td>BibArticle</td><td>He B, Gampe RT, Jr., Kole AJ, Hnat AT, Stanley TB, An G et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004; 16(3):425&#8211;438.</td><td><a href=http://dx.doi.org/10.1016/j.molcel.2004.09.036>10.1016/j.molcel.2004.09.036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_6</td><td>BibArticle</td><td>Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2004; 2(9):E274.</td><td><a href=http://dx.doi.org/10.1371/journal.pbio.0020274>10.1371/journal.pbio.0020274</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_6</td><td>BibArticle</td><td>Estebanez-Perpina E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD et al. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 2005; 280(9):8060&#8211;8068.</td><td><a href=http://dx.doi.org/10.1074/jbc.M407046200>10.1074/jbc.M407046200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_6</td><td>BibArticle</td><td>He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 2000; 275(30):22986&#8211;22994.</td><td><a href=http://dx.doi.org/10.1074/jbc.M002807200>10.1074/jbc.M002807200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_6</td><td>BibArticle</td><td>Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275(34):26164&#8211;26171.</td><td><a href=http://dx.doi.org/10.1074/jbc.M004571200>10.1074/jbc.M004571200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_6</td><td>BibArticle</td><td>Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001; 98(9):4904&#8211;4909.</td><td><a href=http://dx.doi.org/10.1073/pnas.081565498>10.1073/pnas.081565498</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_6</td><td>BibArticle</td><td>Marhefka CA, Moore BM, Bishop TC, Kirkovsky L, Mukherjee A, Dalton JT et al. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem 2001; 44(11):1729&#8211;1740.</td><td><a href=http://dx.doi.org/10.1021/jm0005353>10.1021/jm0005353</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_6</td><td>BibArticle</td><td>Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005; 280(45):37747&#8211;37754.</td><td><a href=http://dx.doi.org/10.1074/jbc.M507464200>10.1074/jbc.M507464200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_6</td><td>BibArticle</td><td>Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 2007; 282(18):13648&#8211;13655.</td><td><a href=http://dx.doi.org/10.1074/jbc.M611711200>10.1074/jbc.M611711200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_6</td><td>BibArticle</td><td>Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11):2511&#8211;2515.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22_6</td><td>BibArticle</td><td>Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21(14):2673&#8211;2678.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.11.102>10.1200/JCO.2003.11.102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_6</td><td>BibArticle</td><td>Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63(1):149&#8211;153.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24_6</td><td>BibArticle</td><td>Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 2005; 102(17):6201&#8211;6206.</td><td><a href=http://dx.doi.org/10.1073/pnas.0500381102>10.1073/pnas.0500381102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_6</td><td>BibArticle</td><td>Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753&#8211;758.</td><td><a href=http://dx.doi.org/10.1038/39645>10.1038/39645</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_6</td><td>BibArticle</td><td>Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7):927&#8211;937.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(00)81717-1>10.1016/S0092-8674(00)81717-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_6</td><td>BibArticle</td><td>Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997; 48:129&#8211;156.</td><td><a href=http://dx.doi.org/10.1146/annurev.med.48.1.129>10.1146/annurev.med.48.1.129</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_6</td><td>BibArticle</td><td>Cantin L, Faucher F, Couture JF, Jesus-Tran KP, Legrand P, Ciobanu LC et al. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 2007; 282(42):30910&#8211;30919.</td><td><a href=http://dx.doi.org/10.1074/jbc.M705524200>10.1074/jbc.M705524200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_6</td><td>BibArticle</td><td>Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295(5564):2465&#8211;2468.</td><td><a href=http://dx.doi.org/10.1126/science.1068537>10.1126/science.1068537</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_6</td><td>BibArticle</td><td>Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997; 11(6):693&#8211;705.</td><td><a href=http://dx.doi.org/10.1210/me.11.6.693>10.1210/me.11.6.693</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_6</td><td>BibArticle</td><td>Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzel T, Renkawitz R. RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem 2002; 277(29):26238&#8211;26243.</td><td><a href=http://dx.doi.org/10.1074/jbc.M203268200>10.1074/jbc.M203268200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_6</td><td>BibArticle</td><td>Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998; 18(3):1369&#8211;1378.</td><td><a href=http://dx.doi.org/10.1128/MCB.18.3.1369>10.1128/MCB.18.3.1369</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, VolumeID, FirstPage, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR33_6</td><td>BibArticle</td><td>Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004; 18(1):70&#8211;85.</td><td><a href=http://dx.doi.org/10.1210/me.2003-0189>10.1210/me.2003-0189</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_6</td><td>BibArticle</td><td>Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005; 280(8):6511&#8211;6519.</td><td><a href=http://dx.doi.org/10.1074/jbc.M408972200>10.1074/jbc.M408972200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_6</td><td>BibArticle</td><td>Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 2002; 16(7):1492&#8211;1501.</td><td><a href=http://dx.doi.org/10.1210/me.16.7.1492>10.1210/me.16.7.1492</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_6</td><td>BibArticle</td><td>Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 2002; 16(4):661&#8211;673.</td><td><a href=http://dx.doi.org/10.1210/me.16.4.661>10.1210/me.16.4.661</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_6</td><td>BibArticle</td><td>Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003; 278(7):5052&#8211;5061.</td><td><a href=http://dx.doi.org/10.1074/jbc.M206374200>10.1074/jbc.M206374200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_6</td><td>BibArticle</td><td>Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 2003; 213(1):79&#8211;85.</td><td><a href=http://dx.doi.org/10.1016/j.mce.2003.10.036>10.1016/j.mce.2003.10.036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_6</td><td>BibArticle</td><td>Wu Y, Kawate H, Ohnaka K, Nawata H, Takayanagi R. Nuclear compartmentalization of N-CoR and its interactions with steroid receptors. Mol Cell Biol 2006; 26(17):6633&#8211;6655.</td><td><a href=http://dx.doi.org/10.1128/MCB.01534-05>10.1128/MCB.01534-05</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_6</td><td>BibArticle</td><td>Yoon HG, Wong J. The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 2005; 20(5):1048&#8211;1060.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41_6</td><td>BibArticle</td><td>Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007; 67(17):8388&#8211;8395.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-0617>10.1158/0008-5472.CAN-07-0617</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_6</td><td>BibArticle</td><td>Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9(3):601&#8211;610.</td><td><a href=http://dx.doi.org/10.1016/S1097-2765(02)00471-9>10.1016/S1097-2765(02)00471-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_6</td><td>BibArticle</td><td>Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004; 18(11):2633&#8211;2648.</td><td><a href=http://dx.doi.org/10.1210/me.2004-0245>10.1210/me.2004-0245</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_6</td><td>BibArticle</td><td>Berrevoets CA, Umar A, Trapman J, Brinkmann AO. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR). Biochem J 2004; 379(Pt 3):731&#8211;738.</td><td><a href=http://dx.doi.org/10.1042/BJ20031456>10.1042/BJ20031456</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_6</td><td>BibArticle</td><td>Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124(3):615&#8211;629.</td><td><a href=http://dx.doi.org/10.1016/j.cell.2005.12.032>10.1016/j.cell.2005.12.032</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_6</td><td>BibArticle</td><td>Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T et al. A randomised comparison of &#8216;Casodex&#8217; (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33(5):447&#8211;456.</td><td><a href=http://dx.doi.org/10.1159/000019634>10.1159/000019634</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_6</td><td>BibArticle</td><td>Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, van Poppel H, Tammela TL et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164(5):1579&#8211;1582.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)67032-2>10.1016/S0022-5347(05)67032-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_6</td><td>BibArticle</td><td>Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51(3):389&#8211;396.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(98)00004-1>10.1016/S0090-4295(98)00004-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_6</td><td>BibArticle</td><td>Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002; 42(5):481&#8211;490.</td><td><a href=http://dx.doi.org/10.1016/S0302-2838(02)00435-9>10.1016/S0302-2838(02)00435-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_6</td><td>BibArticle</td><td>McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97(2):247&#8211;254.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2005.06051.x>10.1111/j.1464-410X.2005.06051.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_6</td><td>BibArticle</td><td>Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176(2):520&#8211;525.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2006.03.057>10.1016/j.juro.2006.03.057</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_6</td><td>BibArticle</td><td>Keating NL, O&#8217;Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24(27):4448&#8211;4456.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.06.2497>10.1200/JCO.2006.06.2497</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_6</td><td>BibArticle</td><td>Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171(6 Pt 1):2272&#8211;2276, quiz.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000127738.94221.da>10.1097/01.ju.0000127738.94221.da</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_6</td><td>BibArticle</td><td>Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22(13):2546&#8211;2553.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.01.174>10.1200/JCO.2004.01.174</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55_6</td><td>BibArticle</td><td>Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15):1036&#8211;1042.</td><td><a href=http://dx.doi.org/10.1056/NEJM199810083391504>10.1056/NEJM199810083391504</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56_6</td><td>BibArticle</td><td>Prostate Cancer Trialists&#8217; Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355(9214):1491&#8211;1498.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)02163-2>10.1016/S0140-6736(00)02163-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_6</td><td>BibArticle</td><td>Fowler JE, Jr., Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154(2 Pt 1):448&#8211;453.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)67071-X>10.1016/S0022-5347(01)67071-X</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, FirstPage, VolumeID, Author_FamilyName_1, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR58_6</td><td>BibArticle</td><td>Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15(8):2928&#8211;2938.</td><td><a href=http://dx.doi.org/10.1097/00005392-199804000-00103>10.1097/00005392-199804000-00103</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR59_6</td><td>BibArticle</td><td>Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159(1):149&#8211;153.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64039-4>10.1016/S0022-5347(01)64039-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60_6</td><td>BibArticle</td><td>Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149(3):607&#8211;609.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_6</td><td>BibArticle</td><td>Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150(3):908&#8211;913.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_6</td><td>BibArticle</td><td>Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43(3):408&#8211;410.</td><td><a href=http://dx.doi.org/10.1016/0090-4295(94)90092-2>10.1016/0090-4295(94)90092-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_6</td><td>BibArticle</td><td>Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol 1995; 153(3 Pt 2):1070&#8211;1072.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR64_6</td><td>BibArticle</td><td>Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157(5):1731&#8211;1735.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64846-8>10.1016/S0022-5347(01)64846-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65_6</td><td>BibArticle</td><td>Huan SD, Gerridzen RG, Yau JC, Stewart DJ. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49(4):632&#8211;634.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(96)00558-4>10.1016/S0090-4295(96)00558-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66_6</td><td>BibArticle</td><td>Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112(11):2393&#8211;2400.</td><td><a href=http://dx.doi.org/10.1002/cncr.23473>10.1002/cncr.23473</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67_6</td><td>BibArticle</td><td>Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of &#8220;hormone-refractory&#8221; prostate cancer. J Natl Cancer Inst 1994; 86(3):222&#8211;227.</td><td><a href=http://dx.doi.org/10.1093/jnci/86.3.222>10.1093/jnci/86.3.222</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68_6</td><td>BibArticle</td><td>Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22(6):1025&#8211;1033.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.06.037>10.1200/JCO.2004.06.037</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_6</td><td>BibArticle</td><td>van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991; 48(2):189&#8211;193.</td><td><a href=http://dx.doi.org/10.1002/ijc.2910480206>10.1002/ijc.2910480206</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_6</td><td>BibArticle</td><td>Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164(1):217&#8211;227.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)63112-4>10.1016/S0002-9440(10)63112-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71_6</td><td>BibArticle</td><td>Mohler JL, Gregory CW, Ford OH, III, Kim D, Weaver CM, Petrusz P et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440&#8211;448.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-1146-03>10.1158/1078-0432.CCR-1146-03</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72_6</td><td>BibArticle</td><td>Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66(5):2815&#8211;2825.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-05-4000>10.1158/0008-5472.CAN-05-4000</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73_6</td><td>BibArticle</td><td>Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68(11):4447&#8211;4454.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-08-0249>10.1158/0008-5472.CAN-08-0249</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74_6</td><td>BibArticle</td><td>Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 2005; 96(6):783&#8211;786.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2005.05714.x>10.1111/j.1464-410X.2005.05714.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_6</td><td>BibArticle</td><td>Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180(3):921&#8211;927.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2008.05.045>10.1016/j.juro.2008.05.045</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76_6</td><td>BibArticle</td><td>Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9(4):401&#8211;406.</td><td><a href=http://dx.doi.org/10.1038/ng0495-401>10.1038/ng0495-401</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77_6</td><td>BibArticle</td><td>Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21):1393&#8211;1398.</td><td><a href=http://dx.doi.org/10.1056/NEJM199505253322101>10.1056/NEJM199505253322101</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78_6</td><td>BibArticle</td><td>Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10(1):33&#8211;39.</td><td><a href=http://dx.doi.org/10.1038/nm972>10.1038/nm972</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79_6</td><td>BibArticle</td><td>Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 2006; 281(38):27882&#8211;27893.</td><td><a href=http://dx.doi.org/10.1074/jbc.M605002200>10.1074/jbc.M605002200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80_6</td><td>BibArticle</td><td>Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3(8):1383&#8211;1388.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR81_6</td><td>BibArticle</td><td>Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984; 132(4):693&#8211;696.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR82_6</td><td>BibArticle</td><td>Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11(13):4653&#8211;4657.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0525>10.1158/1078-0432.CCR-05-0525</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83_6</td><td>BibArticle</td><td>Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004; 64(6):2212&#8211;2221.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-2148-2>10.1158/0008-5472.CAN-2148-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84_6</td><td>BibArticle</td><td>Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28):4563&#8211;4571.</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.15.9749>10.1200/JCO.2007.15.9749</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85_6</td><td>BibArticle</td><td>Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61(11):4315&#8211;4319.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR86_6</td><td>BibArticle</td><td>Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, III, Erdem H et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006; 66(21):10594&#8211;10602.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-1023>10.1158/0008-5472.CAN-06-1023</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87_6</td><td>BibArticle</td><td>Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J et al. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J 2003; 22(6):1336&#8211;1346.</td><td><a href=http://dx.doi.org/10.1093/emboj/cdg120>10.1093/emboj/cdg120</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88_6</td><td>BibArticle</td><td>Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 2000; 14(9):1048&#8211;1057.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89_6</td><td>BibArticle</td><td>Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 2002; 110(1):55&#8211;67.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(02)00809-7>10.1016/S0092-8674(02)00809-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90_6</td><td>BibArticle</td><td>Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004; 116(4):511&#8211;526.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(04)00133-3>10.1016/S0092-8674(04)00133-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91_6</td><td>BibArticle</td><td>Baek SH, Ohgi KA, Nelson CA, Welsbie D, Chen C, Sawyers CL et al. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A 2006; 103(9):3100&#8211;3105.</td><td><a href=http://dx.doi.org/10.1073/pnas.0510842103>10.1073/pnas.0510842103</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92_6</td><td>BibArticle</td><td>Salvati ME, Balog A, Wei DD, Pickering D, Attar RM, Geng J et al. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorg Med Chem Lett 2005; 15(2):389&#8211;393.</td><td><a href=http://dx.doi.org/10.1016/j.bmcl.2004.10.051>10.1016/j.bmcl.2004.10.051</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93_6</td><td>BibArticle</td><td>Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 2008; 7(1):121&#8211;132.</td><td><a href=http://dx.doi.org/10.1158/1535-7163.MCT-07-0581>10.1158/1535-7163.MCT-07-0581</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94_6</td><td>BibArticle</td><td>Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 2008; 101(9):1084&#8211;1089.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2008.07509.x>10.1111/j.1464-410X.2008.07509.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>